Abeona Therapeutics Reports Executive Leadership and Board of Directors Changes

Abeona Therapeutics Inc. (ABEO) on September 28, 2020 publicized that João Siffert, M.D. resigned from his positions as CEO, Head of Research and Development, and Chief Medical Officer, as well as member of the Board of Directors, on September 23, 2020. On September 27, 2020, Brian Pereira, M.D., Stefano Buono, Stephen B. Howell, M.D., George Migausky and Shawn Tomasello each announced that they had stepped down from the Board, effective immediately.

Any director did not have any reason for their resignation and no director point out any disagreements with the Company.

B. Riley FBR announced it was Initiated coverage of Abeona Therapeutics Inc. in a research note on September 18, 2020. SVB Leerink rated the stock as an Outperform in a research noted published on February 10, 2020. Cantor Fitzgerald rated the stock as a Neutral in a research note published on December 10, 2019.

SCO CAPITAL PARTNERS LLC, the Director of Abeona Therapeutics Inc., sold 1989.0 shares at the valuation of $2.00 during an exchange that occurred on Sep 15, which implies that SCO CAPITAL PARTNERS LLC is holding 11,919,292 shares at the estimation of $3,981.

In another transaction, on Sep 11, Director of Abeona Therapeutics Inc., SCO CAPITAL PARTNERS LLC, sold 4600.0 shares at the price of $2.01. After this activity, SCO CAPITAL PARTNERS LLC now keeps 11,921,281 shares of Abeona Therapeutics Inc., esteemed at $9,244.

ABEO Recent Trade

The share price of ABEO descended by -$0.09 during the exchanging session on 09/30/20 to exchange at $1.02. Abeona Therapeutics Inc. stock has an exchanging volume of 6.63 million shares, which is high, contrasted with its 3-months average volume of 1.16M shares. Its market capitalization has now reached to $90.65M.

ABEO Past Trading Activity

The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, ABEO price has dropped by -44.26%. In the course of past three months sees the stock go down around -64.21%, while it has lost -48.74% over the past six months and -68.81% since the start of the year.

ABEO Earning History

Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), Abeona Therapeutics Inc. posted -$0.14 earnings per share (EPS) which was above the consensus estimate of -$0.17 by $0.03, which represents to an expansion by 17.60%.

ABEO Price Performance

Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Abeona Therapeutics Inc. has seen its stock exchanging -73.02% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +2.00% above its three-month low. A more extensive look sees ABEO exchanging -80.35% beneath its 52-week high and -4.67% above from its 52-week low price.

ABEO Instability & Beta Factor

The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 15.35%, while it has a month to month instability of 10.12%. The company has an ATR (Average True Range) of 0.20 and a beta factor of 1.20.

Leave a Comment